Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate

Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology, with great success in the treatment of COVID-19. They have been used massively worldwide. One of the major inconveniences of these vaccines is...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermosilla, Jesús, Alonso-García, Airan, Salmerón-García, Antonio, Cabeza-Barrera, José, Medina-Castillo, Antonio L., Pérez-Robles, Raquel, Navas, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675537/
https://www.ncbi.nlm.nih.gov/pubmed/38005967
http://dx.doi.org/10.3390/vaccines11111635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675537/
https://www.ncbi.nlm.nih.gov/pubmed/38005967
http://dx.doi.org/10.3390/vaccines11111635

Ejemplares similares